JP2020527599A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020527599A5 JP2020527599A5 JP2020522799A JP2020522799A JP2020527599A5 JP 2020527599 A5 JP2020527599 A5 JP 2020527599A5 JP 2020522799 A JP2020522799 A JP 2020522799A JP 2020522799 A JP2020522799 A JP 2020522799A JP 2020527599 A5 JP2020527599 A5 JP 2020527599A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- value
- integer
- independently
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 70
- 150000001875 compounds Chemical class 0.000 claims description 59
- 229910052739 hydrogen Inorganic materials 0.000 claims description 58
- 239000001257 hydrogen Substances 0.000 claims description 58
- 229910052760 oxygen Inorganic materials 0.000 claims description 47
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 238000000034 method Methods 0.000 claims description 42
- 125000001072 heteroaryl group Chemical group 0.000 claims description 37
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 34
- 125000005647 linker group Chemical group 0.000 claims description 32
- 150000003839 salts Chemical class 0.000 claims description 23
- 229910052757 nitrogen Inorganic materials 0.000 claims description 21
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 20
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 20
- 125000004434 sulfur atom Chemical group 0.000 claims description 20
- 210000004027 cell Anatomy 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 18
- 239000012190 activator Substances 0.000 claims description 17
- 125000004429 atom Chemical group 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 230000008685 targeting Effects 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 238000003776 cleavage reaction Methods 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000007017 scission Effects 0.000 claims description 14
- 230000001939 inductive effect Effects 0.000 claims description 13
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 10
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- ZJNLYGOUHDJHMG-UHFFFAOYSA-N 1-n,4-n-bis(5-methylhexan-2-yl)benzene-1,4-diamine Chemical compound CC(C)CCC(C)NC1=CC=C(NC(C)CCC(C)C)C=C1 ZJNLYGOUHDJHMG-UHFFFAOYSA-N 0.000 claims description 8
- -1 HuMax-CD4 Chemical compound 0.000 claims description 8
- 108060003951 Immunoglobulin Proteins 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 102000018358 immunoglobulin Human genes 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 229920001184 polypeptide Polymers 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 239000000126 substance Substances 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- 229960003989 tocilizumab Drugs 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 229960004669 basiliximab Drugs 0.000 claims description 6
- 125000001624 naphthyl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 108091034117 Oligonucleotide Proteins 0.000 claims description 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 5
- 239000003181 biological factor Substances 0.000 claims description 5
- 229960005395 cetuximab Drugs 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 239000005556 hormone Substances 0.000 claims description 5
- 229940088597 hormone Drugs 0.000 claims description 5
- 239000003446 ligand Substances 0.000 claims description 5
- 125000006502 nitrobenzyl group Chemical group 0.000 claims description 5
- 230000002062 proliferating effect Effects 0.000 claims description 5
- 239000000523 sample Substances 0.000 claims description 5
- 239000003053 toxin Substances 0.000 claims description 5
- 231100000765 toxin Toxicity 0.000 claims description 5
- 108700012359 toxins Proteins 0.000 claims description 5
- 101100208110 Arabidopsis thaliana TRX4 gene Proteins 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 4
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 101100425276 Dictyostelium discoideum trxD gene Proteins 0.000 claims description 4
- 108010008165 Etanercept Proteins 0.000 claims description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 4
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 4
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 4
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims description 4
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 4
- 101100154863 Mus musculus Txndc2 gene Proteins 0.000 claims description 4
- 108010038807 Oligopeptides Proteins 0.000 claims description 4
- 102000015636 Oligopeptides Human genes 0.000 claims description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 4
- 108700002718 TACI receptor-IgG Fc fragment fusion Proteins 0.000 claims description 4
- 229960002833 aflibercept Drugs 0.000 claims description 4
- 108010081667 aflibercept Proteins 0.000 claims description 4
- 108010056243 alanylalanine Proteins 0.000 claims description 4
- HAXFWIACAGNFHA-UHFFFAOYSA-N aldrithiol Chemical compound C=1C=CC=NC=1SSC1=CC=CC=N1 HAXFWIACAGNFHA-UHFFFAOYSA-N 0.000 claims description 4
- 229960000548 alemtuzumab Drugs 0.000 claims description 4
- 150000001336 alkenes Chemical class 0.000 claims description 4
- 150000001345 alkine derivatives Chemical class 0.000 claims description 4
- 125000002947 alkylene group Chemical group 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 4
- 229940121375 antifungal agent Drugs 0.000 claims description 4
- 239000003429 antifungal agent Substances 0.000 claims description 4
- 230000000890 antigenic effect Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 4
- 239000003443 antiviral agent Substances 0.000 claims description 4
- 150000001540 azides Chemical class 0.000 claims description 4
- 229960001838 canakinumab Drugs 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 150000001993 dienes Chemical class 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 claims description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 4
- 229960000403 etanercept Drugs 0.000 claims description 4
- 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 claims description 4
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 125000000524 functional group Chemical group 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 229960000578 gemtuzumab Drugs 0.000 claims description 4
- 150000004820 halides Chemical class 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 229940022353 herceptin Drugs 0.000 claims description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 4
- 238000003384 imaging method Methods 0.000 claims description 4
- 230000002519 immonomodulatory effect Effects 0.000 claims description 4
- 229960000598 infliximab Drugs 0.000 claims description 4
- 229960005386 ipilimumab Drugs 0.000 claims description 4
- 150000002527 isonitriles Chemical class 0.000 claims description 4
- 150000002576 ketones Chemical class 0.000 claims description 4
- 229960005108 mepolizumab Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 229960003816 muromonab-cd3 Drugs 0.000 claims description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 4
- 239000002105 nanoparticle Substances 0.000 claims description 4
- 229960005027 natalizumab Drugs 0.000 claims description 4
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 150000007523 nucleic acids Chemical class 0.000 claims description 4
- 229950007283 oregovomab Drugs 0.000 claims description 4
- 229960001972 panitumumab Drugs 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 229960003876 ranibizumab Drugs 0.000 claims description 4
- 229960004641 rituximab Drugs 0.000 claims description 4
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 4
- 229960000575 trastuzumab Drugs 0.000 claims description 4
- MJZJYWCQPMNPRM-UHFFFAOYSA-N 6,6-dimethyl-1-[3-(2,4,5-trichlorophenoxy)propoxy]-1,6-dihydro-1,3,5-triazine-2,4-diamine Chemical compound CC1(C)N=C(N)N=C(N)N1OCCCOC1=CC(Cl)=C(Cl)C=C1Cl MJZJYWCQPMNPRM-UHFFFAOYSA-N 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 3
- 206010025323 Lymphomas Diseases 0.000 claims description 3
- 229960000397 bevacizumab Drugs 0.000 claims description 3
- 229960002224 eculizumab Drugs 0.000 claims description 3
- 229960001743 golimumab Drugs 0.000 claims description 3
- 201000005202 lung cancer Diseases 0.000 claims description 3
- 208000020816 lung neoplasm Diseases 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 3
- 229960001886 rilonacept Drugs 0.000 claims description 3
- 108010046141 rilonacept Proteins 0.000 claims description 3
- 108010017584 romiplostim Proteins 0.000 claims description 3
- 229960004262 romiplostim Drugs 0.000 claims description 3
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 claims description 3
- 125000006850 spacer group Chemical group 0.000 claims description 3
- 229960005267 tositumomab Drugs 0.000 claims description 3
- 229960003824 ustekinumab Drugs 0.000 claims description 3
- ZLKNPIVTWNMMMH-UHFFFAOYSA-N 1-imidazol-1-ylsulfonylimidazole Chemical compound C1=CN=CN1S(=O)(=O)N1C=CN=C1 ZLKNPIVTWNMMMH-UHFFFAOYSA-N 0.000 claims description 2
- MCTWTZJPVLRJOU-UHFFFAOYSA-O 1-methylimidazole Chemical compound CN1C=C[NH+]=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-O 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 2
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 claims description 2
- 206010028372 Muscular weakness Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 239000003153 chemical reaction reagent Substances 0.000 claims description 2
- 239000003638 chemical reducing agent Substances 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims description 2
- 230000003463 hyperproliferative effect Effects 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000004968 inflammatory condition Effects 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 230000036473 myasthenia Effects 0.000 claims description 2
- 239000012038 nucleophile Substances 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 230000003647 oxidation Effects 0.000 claims description 2
- 238000007254 oxidation reaction Methods 0.000 claims description 2
- 208000003154 papilloma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 150000003461 sulfonyl halides Chemical class 0.000 claims description 2
- 150000003852 triazoles Chemical class 0.000 claims description 2
- 210000004881 tumor cell Anatomy 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 claims 2
- 239000003096 antiparasitic agent Substances 0.000 claims 2
- 229940125687 antiparasitic agent Drugs 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 229960003270 belimumab Drugs 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 229960001251 denosumab Drugs 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960001521 motavizumab Drugs 0.000 claims 1
- 229960002087 pertuzumab Drugs 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 0 CC*C(C(C)=O)NC(C)C Chemical compound CC*C(C(C)=O)NC(C)C 0.000 description 7
- 206010008342 Cervix carcinoma Diseases 0.000 description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 201000010881 cervical cancer Diseases 0.000 description 3
- 208000014018 liver neoplasm Diseases 0.000 description 3
- 229950007318 ozogamicin Drugs 0.000 description 3
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 3
- IRZNDKKKFMEHTG-XNIJJKJLSA-N (2r,3s,4r,5r)-2-(hydroxymethyl)-5-[6-[(5-hydroxypyridin-2-yl)methylamino]purin-9-yl]oxolane-3,4-diol Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NCC=3N=CC(O)=CC=3)=C2N=C1 IRZNDKKKFMEHTG-XNIJJKJLSA-N 0.000 description 2
- QDMKPJRHOAHMJH-UHFFFAOYSA-N AMG-1 Natural products C(C)(=O)OCC(C(=O)OC1C(OC2=C1C=C(C(=C2)O)C(C)=O)C(=C)C)=CC QDMKPJRHOAHMJH-UHFFFAOYSA-N 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 229940124339 anthelmintic agent Drugs 0.000 description 2
- 239000000921 anthelmintic agent Substances 0.000 description 2
- IRZNDKKKFMEHTG-UHFFFAOYSA-N eupahyssopin Natural products OC1C(O)C(CO)OC1N1C2=NC=NC(NCC=3N=CC(O)=CC=3)=C2N=C1 IRZNDKKKFMEHTG-UHFFFAOYSA-N 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- KKHFRAFPESRGGD-UHFFFAOYSA-N 1,3-dimethyl-7-[3-(n-methylanilino)propyl]purine-2,6-dione Chemical compound C1=NC=2N(C)C(=O)N(C)C(=O)C=2N1CCCN(C)C1=CC=CC=C1 KKHFRAFPESRGGD-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- NOKHEHFYTNFBEL-UHFFFAOYSA-N CCC1=CCCC=C1 Chemical compound CCC1=CCCC=C1 NOKHEHFYTNFBEL-UHFFFAOYSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 229940126592 Ibritsumomab Drugs 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 210000001109 blastomere Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 229950007217 tremelimumab Drugs 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2017-0084805 | 2017-07-04 | ||
| KR20170084805 | 2017-07-04 | ||
| US201762597226P | 2017-12-11 | 2017-12-11 | |
| US62/597,226 | 2017-12-11 | ||
| PCT/IB2018/000847 WO2019008441A1 (en) | 2017-07-04 | 2018-07-03 | COMPOUNDS COMPRISING A CLIABABLE BIT AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020527599A JP2020527599A (ja) | 2020-09-10 |
| JP2020527599A5 true JP2020527599A5 (https=) | 2021-08-05 |
| JP7174757B2 JP7174757B2 (ja) | 2022-11-17 |
Family
ID=67702070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020522799A Active JP7174757B2 (ja) | 2017-07-04 | 2018-07-03 | 切断可能なリンカーを含む化合物及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11753431B2 (https=) |
| EP (1) | EP3649142A4 (https=) |
| JP (1) | JP7174757B2 (https=) |
| KR (1) | KR102710962B1 (https=) |
| CN (3) | CN120682290A (https=) |
| AU (2) | AU2018295540B2 (https=) |
| BR (1) | BR112019028295A2 (https=) |
| CA (1) | CA3068800A1 (https=) |
| IL (2) | IL271755A (https=) |
| MX (1) | MX2019015940A (https=) |
| TW (1) | TWI801396B (https=) |
| WO (1) | WO2019008441A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120682290A (zh) | 2017-07-04 | 2025-09-23 | 尹图赛利有限公司 | 包含可裂解接头的化合物及其用途 |
| MX2020012718A (es) * | 2018-05-29 | 2021-02-16 | Intocell Inc | Derivados de benzodiazepinas novedosos y usos de los mismos. |
| WO2020038278A1 (zh) * | 2018-08-21 | 2020-02-27 | 深圳市塔革特生物医药科技有限公司 | 新型喜树碱衍生物及其制备方法和应用 |
| CN112930350A (zh) | 2018-10-31 | 2021-06-08 | 尹图赛利有限公司 | 稠合杂环苯并二氮杂䓬衍生物及其用途 |
| KR20210099658A (ko) * | 2019-01-03 | 2021-08-12 | 주식회사 인투셀 | 절단가능 링커를 포함하는 화합물 및 이의 용도 |
| WO2020141459A1 (en) * | 2019-01-03 | 2020-07-09 | Intocell, Inc. | Compounds comprising cleavable linker and uses thereof |
| WO2020232247A1 (en) | 2019-05-14 | 2020-11-19 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| CA3145913A1 (en) | 2019-07-29 | 2021-02-04 | James Everett Dahlman | Nanomaterials containing constrained lipids and uses thereof |
| IL292328B2 (en) * | 2019-10-28 | 2025-10-01 | Geron Corp | Succinylate-converted 3-(amido fatty acid)-2-hydroxy-1-(protected hydroxy)-propane salts, amorphous solids and methods for their preparation |
| KR20220108783A (ko) * | 2019-12-02 | 2022-08-03 | 주식회사 인투셀 | 분자 접합과 관련된 조성물 및 방법 |
| IL294318A (en) | 2020-01-09 | 2022-08-01 | Guide Therapeutics Llc | Nanomaterials |
| JP2023528825A (ja) * | 2020-05-28 | 2023-07-06 | アンセルム | 血栓の予防、処置および診断のための化合物 |
| IL298999A (en) | 2020-06-11 | 2023-02-01 | Provention Bio Inc | Methods and compositions for the prevention of type 1 diabetes |
| BR112022026401A2 (pt) * | 2020-06-26 | 2023-03-14 | Intocell Inc | Conjugados anticorpo-fármaco compreendendo anticorpos anti-b7-h3 |
| CN116761888A (zh) | 2021-01-20 | 2023-09-15 | 比姆医疗股份有限公司 | 纳米材料 |
| EP4281080A4 (en) | 2021-01-20 | 2025-09-24 | Beam Therapeutics Inc | NANOMATERIALS COMPRISING A BIODEGRADABLE ELEMENT |
| JP2024503441A (ja) * | 2021-01-20 | 2024-01-25 | ビーム セラピューティクス インク． | イオン化可能な脂質を含むナノ材料 |
| EP4326737A1 (en) * | 2021-04-19 | 2024-02-28 | Neurotrauma Sciences LLC | Salts and crystalline forms of (3e) 3-[o-[(phosphonooxy)methyl]oxime]-pregn-4-ene-3, 20-dione and related uses |
| JP2024520444A (ja) | 2021-05-24 | 2024-05-24 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を治療するための方法 |
| EP4377292A1 (en) * | 2021-07-28 | 2024-06-05 | Ramot at Tel-Aviv University Ltd. | Water soluble prodrug, conjugates and uses thereof |
| CN114773433B (zh) * | 2022-06-23 | 2022-09-06 | 北京肿瘤医院(北京大学肿瘤医院) | 一种cd25靶向多肽、分子探针及应用 |
| CA3260437A1 (en) | 2022-07-20 | 2024-01-25 | Beam Therapeutics Inc. | NANOMATERIALS INCLUDING TRIOLS |
| GB202306325D0 (en) * | 2023-04-28 | 2023-06-14 | Iksuda Therapeutics Ltd | Antibody-drug conjugate compounds, and methods of use and treatment |
| AU2024282578A1 (en) * | 2023-05-31 | 2025-12-04 | Full-Life Technologies Uk Limited | Radioligands for targeting cell surface receptors and uses thereof |
| WO2025237246A1 (en) * | 2024-05-11 | 2025-11-20 | Westlake Laboratory Of Life Sciences And Biomedicine | Novel covalent protein and use thereof |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1182232B (de) | 1963-03-08 | 1964-11-26 | Hans J Zimmer Verfahrenstechni | Verfahren zur Herstellung von Trialkylaryloxysilanen |
| CH565791A5 (https=) | 1972-07-11 | 1975-08-29 | Sandoz Ag | |
| US4540828A (en) | 1982-06-01 | 1985-09-10 | Vista Chemical Company | Catalysts for alkoxylation reactions |
| JPS5978171A (ja) | 1982-10-26 | 1984-05-04 | Ikeda Mohandou:Kk | 複素環式化合物 |
| DE3632329A1 (de) | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| JP3041736B2 (ja) | 1991-11-01 | 2000-05-15 | コニカ株式会社 | ハロゲン化銀写真感光材料 |
| ATE218132T1 (de) | 1994-10-14 | 2002-06-15 | Yamanouchi Pharma Co Ltd | Azol-derivate |
| CN103030617A (zh) * | 2004-03-16 | 2013-04-10 | 贝林格尔.英格海姆国际有限公司 | 吡喃葡萄糖基取代的苯基衍生物、含该化合物的药物、其用途及其制造方法 |
| DE102004012676A1 (de) * | 2004-03-16 | 2005-10-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Glucopyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| JP2005291974A (ja) | 2004-03-31 | 2005-10-20 | Kyocera Chemical Corp | フェルダジル基を有する磁性有機粒子、粒子固定方法及びマイクロアレイ |
| WO2006125293A1 (en) * | 2005-05-27 | 2006-11-30 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
| EP1867729A1 (en) | 2006-06-14 | 2007-12-19 | Libragen | Water soluble phenolics derivatives with dermocosmetic and therapeutic applications |
| CN101959900A (zh) * | 2007-12-26 | 2011-01-26 | 盐野义制药株式会社 | 糖肽类抗生素糖基化衍生物 |
| CN104185477B (zh) * | 2011-11-17 | 2017-05-24 | 辉瑞公司 | 细胞毒性肽及其抗体‑药物缀合物 |
| TWI585115B (zh) * | 2011-12-15 | 2017-06-01 | 普利司通股份有限公司 | 經穩定之多價陰離子聚合反應引發劑及其製備方法 |
| ES2781523T3 (es) | 2012-07-12 | 2020-09-02 | Hangzhou Dac Biotech Co Ltd | Conjugados de moléculas de unión celular con agentes citotóxicos |
| US9834575B2 (en) * | 2013-02-26 | 2017-12-05 | Triact Therapeutics, Inc. | Cancer therapy |
| US9499528B2 (en) | 2013-04-08 | 2016-11-22 | The University Of Akron | Class of near infrared molecular probes for biological applications |
| DK3092256T3 (da) | 2014-01-10 | 2022-06-20 | Birdie Biopharmaceuticals Inc | Forbindelser og sammensætninger til immunterapi |
| KR101628872B1 (ko) | 2014-05-28 | 2016-06-09 | 주식회사 레고켐 바이오사이언스 | 자가-희생 기를 포함하는 화합물 |
| WO2016029324A1 (en) * | 2014-08-29 | 2016-03-03 | Rsem, Limited Partnership | Azasulfurylpeptide-based cd36 modulators and uses thereof |
| US10035526B2 (en) | 2014-12-03 | 2018-07-31 | New York Air Brake, LLC | Brake piston assembly |
| US10370407B2 (en) | 2015-01-21 | 2019-08-06 | The Regents Of The University Of California | Affinity-assisted protein modification and recycling |
| CN107922375B (zh) | 2015-07-30 | 2020-05-22 | 正大天晴药业集团股份有限公司 | 靶向idh2突变的抗肿瘤化合物及其使用方法 |
| WO2017044043A1 (en) * | 2015-09-09 | 2017-03-16 | Agency For Science, Technology And Research | Process for direct amidation of amines via rh(i)-catalyzed addition of boroxines |
| KR101766822B1 (ko) * | 2015-09-10 | 2017-08-24 | 서울대학교산학협력단 | 디페닐설페이트 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 포함하는 c형 간염 바이러스 관련 질환의 예방 또는 치료용 약학적 조성물 |
| AU2016359235B2 (en) | 2015-11-25 | 2022-09-15 | Ligachem Biosciences Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
| WO2018053552A2 (en) | 2016-09-19 | 2018-03-22 | Cellerant Therapeutics, Inc. | Isoquinolidinobenzodiazepines |
| WO2018124758A2 (ko) | 2016-12-28 | 2018-07-05 | 주식회사 인투셀 | 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물 |
| CN120682290A (zh) | 2017-07-04 | 2025-09-23 | 尹图赛利有限公司 | 包含可裂解接头的化合物及其用途 |
| MX2020012718A (es) | 2018-05-29 | 2021-02-16 | Intocell Inc | Derivados de benzodiazepinas novedosos y usos de los mismos. |
| CN112930350A (zh) | 2018-10-31 | 2021-06-08 | 尹图赛利有限公司 | 稠合杂环苯并二氮杂䓬衍生物及其用途 |
| WO2020141459A1 (en) | 2019-01-03 | 2020-07-09 | Intocell, Inc. | Compounds comprising cleavable linker and uses thereof |
| KR20210099658A (ko) | 2019-01-03 | 2021-08-12 | 주식회사 인투셀 | 절단가능 링커를 포함하는 화합물 및 이의 용도 |
-
2018
- 2018-07-03 CN CN202510782629.4A patent/CN120682290A/zh active Pending
- 2018-07-03 AU AU2018295540A patent/AU2018295540B2/en not_active Expired - Fee Related
- 2018-07-03 CN CN201880056603.XA patent/CN111278845A/zh active Pending
- 2018-07-03 BR BR112019028295-5A patent/BR112019028295A2/pt active Search and Examination
- 2018-07-03 MX MX2019015940A patent/MX2019015940A/es unknown
- 2018-07-03 KR KR1020207003188A patent/KR102710962B1/ko active Active
- 2018-07-03 WO PCT/IB2018/000847 patent/WO2019008441A1/en not_active Ceased
- 2018-07-03 CN CN202510782597.8A patent/CN120682289A/zh active Pending
- 2018-07-03 JP JP2020522799A patent/JP7174757B2/ja active Active
- 2018-07-03 US US16/628,482 patent/US11753431B2/en active Active
- 2018-07-03 EP EP18828726.2A patent/EP3649142A4/en active Pending
- 2018-07-03 CA CA3068800A patent/CA3068800A1/en active Pending
- 2018-07-04 TW TW107123170A patent/TWI801396B/zh active
-
2019
- 2019-12-30 IL IL271755A patent/IL271755A/en unknown
-
2023
- 2023-05-30 US US18/203,326 patent/US12479927B2/en active Active
- 2023-08-15 AU AU2023216777A patent/AU2023216777C1/en active Active
-
2025
- 2025-05-04 IL IL320635A patent/IL320635A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020527599A5 (https=) | ||
| JP2022515885A5 (https=) | ||
| CN114456186B (zh) | 一种喜树碱类衍生物及其配体-药物偶联物 | |
| JP2022515884A5 (https=) | ||
| TWI715611B (zh) | 抗體藥物偶聯物的共價鍵連接子及其製備方法與應用 | |
| JP7393810B2 (ja) | 部位特異的抗体コンジュゲーション及びその具体例としての抗体－薬物コンジュゲート | |
| JP2017531028A5 (https=) | ||
| CN111643676B (zh) | 一种双特异性二聚体、双特异性二聚体-药物偶联物及其应用 | |
| CN112543752A (zh) | 连接子、含连接子的抗体偶联药物及连接子的用途 | |
| EP3186278A1 (en) | Internalizing moieties for treatment of cancer | |
| IL324591A (en) | Improved antibody-drug conjugate production methods | |
| JP2024501894A5 (https=) | ||
| Figini et al. | Conversion of murine antibodies to human antibodies and their optimization for ovarian cancer therapy targeted to the folate receptor | |
| KR102014383B1 (ko) | G 단백질 연결 수용체의 활성 조절 인간 항체 | |
| TW202200213A (zh) | 抗體藥物複合體 | |
| JP2025500342A5 (https=) | ||
| NL2020121B1 (en) | Platinum-based functional moieties for preparing cell targeting conjugates | |
| WO2024109935A1 (zh) | 芦竹碱-铂（iv）配合物及其制备方法和抗肿瘤用途 | |
| Calce et al. | HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor | |
| WO2023143319A1 (zh) | 抗体药物偶联物、药物组合物及用途 | |
| JP2022515880A (ja) | Ｔａｍおよびｍｅｔキナーゼの阻害薬としてのキノリン化合物 | |
| AU2004292933B2 (en) | Targeting of Erb antigens | |
| RU2020104697A (ru) | Соединения, содержащие расщепляемый линкер, и способы их применения | |
| US20150182634A1 (en) | Molecular Design and Chemical Synthesis of Pharmaceutical-Ligands and Pharmaceutical-Pharmaceutical Analogs with Multiple Mechanisms of Action | |
| JP2025508868A5 (https=) |